As discussed last month, the FTC sent letters to 10 pharmaceutical companies, asserting that their listing of over 100 patents in FDA's Orange Book for a variety of products was improper. Shortly thereafter, the FTC began using the administrative process with FDA to challenge these patent listings, and all of the companies had until December 16, 2023 to respond.
It appears that prior to this deadline at least two companies – Impax Labs and Kaleo, Inc. – may have felt pressure to reconsider their patent listings.
Specifically, Impax delisted both of its patents directed to Adrenaclick, the same patents that the FTC had noticed in its November 7, 2023 letter. There are currently no approved generic applicants for Adrenaclick, and no additional patents directed to Adrenaclick in the Orange Book. Similarly, Kaleo delisted eight patents directed to AUVI-Q, the same patents that the FTC had noticed in its letter to Kaleo. Given that the Orange Book lists more than twenty patents for AUVI-Q, it seems that any potential generic applicant still has quite the battle ahead.
It will be interesting to continue to monitor for any further patent delistings, particularly with the December 16, 2023 deadline coming up. Time will tell whether the FTC will take any further action against those companies that don't follow Kaleo and Impax's paths. And, it remains to be seen whether we can expect further fallout in private litigation from FTC's recent, more aggressive actions in this area.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.